Eco-friendly second-derivative synchronous fluorescence method for the determination of empagliflozin and sitagliptin in tablets and plasma samples. [PDF]
Sci RepMohamad AAA +3 more
europepmc +1 more source
Diabetes Mellitus 2 is a progressive metabolic disease that has Insulin Resistance and impaired insulin secretion. T2DM usually produces prolonged high blood glucose levels (hyperglycaemia), which makes medication to treat T2DM require combining different types of medication over time. The research described in this paper evaluates the performance of a
openaire +2 more sources
Eyedrop Administration of DPP-4 Inhibitors: A New Strategy for Treating Early Stages of Diabetic Retinal Disease. [PDF]
Int J Mol SciRamos H +3 more
europepmc +1 more source
Glycaemic and Cardiometabolic Outcomes of Empagliflozin Versus Sitagliptin Added to Metformin in T2DM: Insights From a Systematic Review and Meta-Analysis. [PDF]
Endocrinol Diabetes MetabAshraf S +10 more
europepmc +1 more source
Five-year follow-up of incretin-based therapy in a patient with KCNJ11-related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction. [PDF]
J Diabetes InvestigOhkuma T +4 more
europepmc +1 more source
Sitagliptin Modulates Functional and Phenotypic Properties of Human Neutrophils Under Normal- and High-Glucose Conditions In Vitro. [PDF]
MoleculesMališ V +8 more
europepmc +1 more source
Low dose of sitagliptin: effectively prevent liver aGVHD and accelerate neutrophil engraftment. [PDF]
Ann HematolLiu M, Zhong Z, Wang H.
europepmc +1 more source
Limited Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Appetite and Body Weight: Evidence From Clinical and Rodent Studies. [PDF]
J Korean Med SciLee J +8 more
europepmc +1 more source
Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS). [PDF]
PLoS OneXiong W, Li Y, Huang J, He G, Sun J.
europepmc +1 more source